The Position

Wave is looking for a summer intern to join the Patient Advocacy team. Our team is responsible for communicating with external stakeholders about our company and our programs while also gathering critical insights to help inform Wave’s work. The team also collaborates with Human Resources to enable a well-informed and motived workforce. The Patient Advocacy team develops productive partnerships and facilitates dialogue with patient advocacy organizations centered around advancing mutual priorities and improving treatment, care, services and support for persons diagnosed with rare and common diseases. Community engagement activities are focused on seeking to better understand the experience of people living with rare and common diseases and identifying opportunities to support the community. The team partners closely with internal cross-functional stakeholders to integrate community insights into Wave’s programs, decision-making, and communications.

Responsibilities

• Enhancement and development of internal mechanisms to share community insights
• Refinement of external community-facing materials
• Research and analysis of healthcare and advocacy ecosystems

Requirements

• Preferred majors: Pre-Med/Nursing/Health Sciences, Psychology/Social Work, Public Policy/Public Health, or Communications
• Passion for making an impact in the lives of persons living with serious diseases
• Strong communication skills
• Ability to take initiative
• Ability to think “outside of the box” and propose innovative approaches and creative solutions 
• Ability to build relationships and work collaboratively

Company

Wave Life Sciences is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Our RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Our toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing us with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Our diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a clinical program in obesity and a preclinical program in NASH/MASH. Driven by the calling to “Reimagine Possible”, we are leading the charge toward a world in which human potential is no longer hindered by the burden of disease.